Merck & Co., Inc. $MRK Stock Position Trimmed by Florida Trust Wealth Management Co

Florida Trust Wealth Management Co trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 1.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 511,020 shares of the company’s stock after selling 9,161 shares during the period. Merck & Co., Inc. accounts for approximately 1.5% of Florida Trust Wealth Management Co’s holdings, making the stock its 15th biggest position. Florida Trust Wealth Management Co’s holdings in Merck & Co., Inc. were worth $53,790,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of MRK. Ethos Financial Group LLC increased its stake in shares of Merck & Co., Inc. by 25.7% in the fourth quarter. Ethos Financial Group LLC now owns 8,128 shares of the company’s stock valued at $863,000 after purchasing an additional 1,664 shares during the period. Nvwm LLC grew its holdings in Merck & Co., Inc. by 2,930.5% in the 4th quarter. Nvwm LLC now owns 32,941 shares of the company’s stock worth $3,467,000 after buying an additional 31,854 shares in the last quarter. Reliant Investment Management LLC bought a new position in Merck & Co., Inc. in the 4th quarter worth approximately $243,000. Signaturefd LLC increased its position in Merck & Co., Inc. by 9.9% in the 4th quarter. Signaturefd LLC now owns 51,409 shares of the company’s stock valued at $5,411,000 after acquiring an additional 4,644 shares during the period. Finally, Advocate Group LLC raised its stake in Merck & Co., Inc. by 1.2% during the 4th quarter. Advocate Group LLC now owns 98,811 shares of the company’s stock valued at $10,401,000 after acquiring an additional 1,214 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Analyst Upgrades and Downgrades

MRK has been the subject of a number of analyst reports. BMO Capital Markets upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $82.00 to $130.00 in a research report on Thursday, December 18th. TD Cowen lifted their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research note on Tuesday, January 20th. Bank of America upped their price objective on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Guggenheim raised their target price on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Finally, Barclays began coverage on shares of Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $127.13.

Merck & Co., Inc. Trading Down 0.2%

Shares of Merck & Co., Inc. stock opened at $120.62 on Friday. The business has a fifty day simple moving average of $117.72 and a 200-day simple moving average of $103.23. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The firm has a market cap of $298.21 billion, a price-to-earnings ratio of 16.57, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same period in the previous year, the company earned $1.72 earnings per share. Merck & Co., Inc.’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the transaction, the chief marketing officer owned 70,615 shares in the company, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the stock in a transaction on Friday, February 6th. The shares were sold at an average price of $121.87, for a total value of $1,828,050.00. Following the sale, the insider owned 21,197 shares of the company’s stock, valued at $2,583,278.39. This trade represents a 41.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 320,176 shares of company stock worth $38,281,735. Company insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.